Literature DB >> 2822387

Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon.

L Zardi1, B Carnemolla, A Siri, T E Petersen, G Paolella, G Sebastio, F E Baralle.   

Abstract

Purification and amino acid sequence analysis of a proteolytic fragment of fibronectin (FN) from transformed human cells demonstrated that a high percentage of these FN molecules contains an extra amino acid sequence which is present only in a very low percentage of FN molecules from normal fibroblasts and is undetectable in plasma FN. This new amino acid sequence introduces into the FN molecule a site very sensitive to a number of proteolytic enzymes. By analyzing the cellular mRNA and genomic clones, we have demonstrated that this sequence derives from a differential splicing pattern of the FN mRNA precursors, which leads in transformed cells to a high-level expression of an extra type III homology repeat (ED-B) coded for by a previously unobserved exon. Here we also report the complete sequence of this new exon. These results demonstrate that in malignant cells the mechanisms regulating the splicing of FN mRNA precursors are altered.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2822387      PMCID: PMC553637          DOI: 10.1002/j.1460-2075.1987.tb02509.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  32 in total

1.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Location of the cell-attachment site in fibronectin with monoclonal antibodies and proteolytic fragments of the molecule.

Authors:  M D Pierschbacher; E G Hayman; E Ruoslahti
Journal:  Cell       Date:  1981-10       Impact factor: 41.582

4.  Partial primary structure of bovine plasma fibronectin: three types of internal homology.

Authors:  T E Petersen; H C Thøgersen; K Skorstengaard; K Vibe-Pedersen; P Sahl; L Sottrup-Jensen; S Magnusson
Journal:  Proc Natl Acad Sci U S A       Date:  1983-01       Impact factor: 11.205

5.  Cloning in single-stranded bacteriophage as an aid to rapid DNA sequencing.

Authors:  F Sanger; A R Coulson; B G Barrell; A J Smith; B A Roe
Journal:  J Mol Biol       Date:  1980-10-25       Impact factor: 5.469

6.  A simplified procedure for the preparation of antibodies to serum fibronectin.

Authors:  L Zardi; A Siri; B Carnemolla; E Cosulich; G Viale; L Santi
Journal:  J Immunol Methods       Date:  1980       Impact factor: 2.303

7.  Fibronectin--mediator between cells and connective tissue.

Authors:  H Hörmann
Journal:  Klin Wochenschr       Date:  1982-10-15

8.  Isolation of a collagen-binding fragment from fibronectin and cold-insoluble globulin.

Authors:  G Balian; E M Click; E Crouch; J M Davidson; P Bornstein
Journal:  J Biol Chem       Date:  1979-03-10       Impact factor: 5.157

9.  Somatic cell hybrids producing antibodies specific to human fibronectin.

Authors:  L Zardi; B Carnemolla; A Siri; L Santi; R S Accolla
Journal:  Int J Cancer       Date:  1980-03-15       Impact factor: 7.396

10.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease.

Authors:  J M Chirgwin; A E Przybyla; R J MacDonald; W J Rutter
Journal:  Biochemistry       Date:  1979-11-27       Impact factor: 3.162

View more
  83 in total

1.  A real-time in vitro assay for studying functional characteristics of target-specific ultrasound contrast agents.

Authors:  Shiba Joseph; Carsten Olbrich; Julia Kirsch; Michael Hasbach; Andreas Briel; Michael Schirner
Journal:  Pharm Res       Date:  2004-06       Impact factor: 4.200

Review 2.  Molecular targeting of angiogenesis for imaging and therapy.

Authors:  Simon S Brack; Ludger M Dinkelborg; Dario Neri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-08-05       Impact factor: 9.236

3.  Co-assembly of plasma and cellular fibronectins into fibrils in human fibroblast cultures.

Authors:  D M Peters; L M Portz; J Fullenwider; D F Mosher
Journal:  J Cell Biol       Date:  1990-07       Impact factor: 10.539

4.  Loss of EDB+ fibronectin isoform is associated with differentiation of alveolar epithelial cells in human fetal lung.

Authors:  H Arai; H Hirano; S Mushiake; M Nakayama; G Takada; K Sekiguchi
Journal:  Am J Pathol       Date:  1997-08       Impact factor: 4.307

5.  Involvement of O-glycosylation defining oncofetal fibronectin in epithelial-mesenchymal transition process.

Authors:  Leonardo Freire-de-Lima; Kirill Gelfenbeyn; Yao Ding; Ulla Mandel; Henrik Clausen; Kazuko Handa; Sen-Itiroh Hakomori
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-17       Impact factor: 11.205

6.  Alternative splicing of endothelial cell fibronectin mRNA in the IIICS region. Functional significance.

Authors:  O Kocher; S P Kennedy; J A Madri
Journal:  Am J Pathol       Date:  1990-12       Impact factor: 4.307

7.  Hominoid triosephosphate isomerase: regulation of expression of the proliferation specific isozyme.

Authors:  S E Old; L E Landa; H W Mohrenweiser
Journal:  Mol Cell Biochem       Date:  1989-08-15       Impact factor: 3.396

8.  Biodistribution studies with tumor-targeting bispecific antibodies reveal selective accumulation at the tumor site.

Authors:  Thomas List; Dario Neri
Journal:  MAbs       Date:  2012-10-02       Impact factor: 5.857

9.  Sequence analysis and in vivo expression show that alternative splicing of ED-B and ED-A regions of the human fibronectin gene are independent events.

Authors:  G Paolella; C Henchcliffe; G Sebastio; F E Baralle
Journal:  Nucleic Acids Res       Date:  1988-04-25       Impact factor: 16.971

Review 10.  Imaging in targeted delivery of therapy to cancer.

Authors:  Gairin Dancey; Richard H Begent; Tim Meyer
Journal:  Target Oncol       Date:  2009-10-08       Impact factor: 4.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.